title: Bevacizumab-containing chemotherapy for non-small cell lung cancer patients: a population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group.
abstract: To evaluate the efficacy and safety of bevacizumab-containing chemotherapy for non-small cell lung cancer (NSCLC), we performed a population-based observational study. The efficacy and safety of bevacizumab-containing chemotherapy for NSCLC patients were evaluated at 14 sites (17 hospital departments) in a prefecture of Japan between December 2009 and August 2011. Complete data sets were obtained from 159 patients with NSCLC. The median age was 66 years, and 34.0 % of the patients were 70 years or older. The overall response rate to bevacizumab therapy was 41.6 %, and the disease control rate was 78.5 %. In 88 patients who received bevacizumab-containing chemotherapy as first-line therapy, the response and disease control rates were 55.0 and 78.9 %, respectively. The incidence of clinically significant (grade 3 or more) adverse events was generally low: proteinuria occurred in 2 (1.3 %) patients, hypertension in 2 (1.3 %), hemoptysis in 1 (0.6 %), and interstitial pneumonia in 1 (0.6 %). The time to treatment failure (TTF) in the 159 patients was 169 days, and the median overall survival (OS) was 580 days. In patients who received bevacizumab-containing chemotherapy as first-line therapy, the TTF and OS were 152 and 520 days, respectively. The difference in TTF between patients who received bevacizumab-containing chemotherapy as first-line therapy and those who received it as second-line or later-line therapy was not significant (p = 0.4971). With regard to first-line therapy, the difference in TTF between patients treated with carboplatin + pemetrexed + bevacizumab and those treated with carboplatin + paclitaxel + bevacizumab was not significant (p = 0.9435). We deduced that bevacizumab-containing chemotherapy is effective against NSCLC and also tolerable in clinical practice.
authors.affiliation: Ibaraki Medical Center Hospital, Tokyo Medical University, Ami, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Nakamura
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Satoh
authors.forename: Takayuki
authors.initials: T
authors.lastname: Kaburagi
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Nishimura
authors.forename: Yoko
authors.initials: Y
authors.lastname: Shinohara
authors.forename: Masaharu
authors.initials: M
authors.lastname: Inagaki
authors.forename: Takeo
authors.initials: T
authors.lastname: Endo
authors.forename: Takefumi
authors.initials: T
authors.lastname: Saito
authors.forename: Kenji
authors.initials: K
authors.lastname: Hayashihara
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Hizawa
authors.forename: Koichi
authors.initials: K
authors.lastname: Kurishima
authors.forename: Takeshi
authors.initials: T
authors.lastname: Nawa
authors.forename: Katsunori
authors.initials: K
authors.lastname: Kagohashi
authors.forename: Koji
authors.initials: K
authors.lastname: Kishi
authors.forename: Hiroichi
authors.initials: H
authors.lastname: Ishikawa
authors.forename: Hideo
authors.initials: H
authors.lastname: Ichimura
authors.forename: Toshio
authors.initials: T
authors.lastname: Hashimoto
authors.forename: Yukio
authors.initials: Y
authors.lastname: Sato
authors.forename: Mitsuaki
authors.initials: M
authors.lastname: Sakai
authors.forename: Koichi
authors.initials: K
authors.lastname: Kamiyama
authors.forename: Takeshi
authors.initials: T
authors.lastname: Matsumura
authors.forename: Koji
authors.initials: K
authors.lastname: Unoura
authors.forename: Kinya
authors.initials: K
authors.lastname: Furukawa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D000068258:Bevacizumab; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D005971:Glutamates / Q000008:administration & dosage / Q000009:adverse effects; D006147:Guanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D006801:Humans; D007564:Japan; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D000068437:Pemetrexed; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D005971:Glutamates; D000068437:Pemetrexed; D000068258:Bevacizumab; D006147:Guanine; D016190:Carboplatin; D017239:Paclitaxel